Diagnosis and Management of Diabetes Mellitus

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Diagnosis and Prognosis".

Deadline for manuscript submissions: 31 March 2026 | Viewed by 664

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biochemistry and Molecular Genetics, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA
Interests: proteomics; metabolomics; coagulopathy; diabetes; natural products; public health; molecular biology; bioinformatics

E-Mail Website
Guest Editor
Department of Laboratory Medicine, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore
Interests: endocrine biomarkers (thyroid disease, diabetes); cardiac biomarkers (troponin, BNP, Galactin3, Lipids); COVID-19 biomarkers (antibodies, antigen); cancer biomarkers (HE4, circulating tumor cells); lab management (POCT, accreditation, LEAN)
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue will focus on highlighting advanced diagnostic approaches, molecular biomarkers, integrative technologies, and improved therapeutic strategies for better control of diabetes mellitus and its complications. The integration of diagnostic precision into therapeutic decision-making is critical in addressing the complex nature of diabetes and preventing its progression to complications such as nephropathy, retinopathy, and cardiovascular disease. Submissions that explore innovative diagnostic techniques, population-specific interventions, and novel management approaches, including, but not limited to, personalized medicine, lifestyle interventions, and phytotherapeutics, are welcome. We invite all researchers in this field to submit contributions to this Special Issue in the form of systematic reviews, original research articles, or communications.

Dr. Franklyn Iheagwam
Prof. Dr. Aw Tar-Choon
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes diagnosis
  • glycemic monitoring
  • personalized treatment
  • chronic complications
  • point-of-care testing
  • insulin resistance
  • diagnostic biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1035 KB  
Article
Quantitative Bone SPECT/CT in Diabetic Foot Osteomyelitis: Diagnostic Performance Within-Patient Lesion–Contralateral Separation and Associations with Inflammatory Burden
by Hulya Peker Yalcin, Pınar Akkus Gunduz, Mehmet Samsum, Emel Colak Samsum, Aysenur Erol, Umut Mert Turan, Gulsah Gedikli Turgut, Aysun Yalci, Nihal Yesildag, Musa Fatih Yalcin and Nesibe Zeynep Eryavuz
Diagnostics 2025, 15(22), 2907; https://doi.org/10.3390/diagnostics15222907 - 17 Nov 2025
Viewed by 510
Abstract
Objective: We sought to assess the diagnostic performance of quantitative bone SPECT/CT standardized uptake values (SUVs) in diabetic foot osteomyelitis (DFO) and their associations with inflammatory biomarkers. Methods: We retrospectively reviewed 150 consecutive patients who underwent three-phase bone scintigraphy and foot [...] Read more.
Objective: We sought to assess the diagnostic performance of quantitative bone SPECT/CT standardized uptake values (SUVs) in diabetic foot osteomyelitis (DFO) and their associations with inflammatory biomarkers. Methods: We retrospectively reviewed 150 consecutive patients who underwent three-phase bone scintigraphy and foot SPECT/CT (November 2016–December 2024) for DFO before antibiotic treatment; 117 with complete imaging and laboratory data were analyzed. Lesion and contralateral SUVs (SUVmax, SUVmean) were compared. Receiver operating characteristic (ROC) curves were used to determine discrimination and optimal cut-offs (Youden index). Associations with biomarkers (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), CRP/albumin (ESR × CRP) and hematologic/coagulation indices including mean corpuscular hemoglobin (MCH) and activated partial thromboplastin time (aPTT) were evaluated using Spearman correlations. Results: Lesion uptake and contralateral uptake were SUVmax 10.94 ± 7.36 vs. 3.62 ± 1.70; SUVmean 4.38 ± 3.63 vs. 0.93 ± 0.50. Discrimination was excellent; SUVmax was AUC 0.921 (cut-off 4.47; sensitivity 0.93; specificity 0.75) and SUVmean was AUC 0.961 (cut-off 1.49; sensitivity 0.91; specificity 0.89). CRP and ESR showed weak but consistent positive correlations with SUVs (ρ ≈ 0.25–0.30). The ESR × CRP value correlated most strongly (e.g., with SUVmean ρ = 0.35), and CRP/albumin showed a modest positive association. MCH (ρ ≈ −0.20) and aPTT (ρ ≈ −0.37) were inversely related. Conclusions: Quantitative SPECT/CT provides excellent lesion–contralateral discrimination in DFO. SUVs—particularly SUVmean—track inflammatory burden, supporting their use as practical quantitative adjuncts to clinical and laboratory assessment. Study-specific cut-offs are promising but require local validation. Full article
(This article belongs to the Special Issue Diagnosis and Management of Diabetes Mellitus)
Show Figures

Figure 1

Back to TopTop